Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
03 January 2024 - 8:05AM
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:
YMAB), a commercial-stage biopharmaceutical company focused on the
development and commercialization of novel radioimmunotherapy and
antibody-based therapeutic products for the treatment of cancer,
today announced that Michael Rossi, President and Chief Executive
Officer, will present at the 42nd Annual J.P. Morgan Healthcare
Conference in San Francisco, CA on Wednesday, January 10, 2024 at
5:15pm PT.
A live webcast of the presentation and any accompanying
presentation materials will be available under the Events section
of the Company’s Investor Relations website at www.ymabs.com. The
webcast will be archived for at least 30 days.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical
company focused on the development and commercialization of novel,
radioimmunotherapy and antibody-based therapeutic cancer products.
The Company’s technologies include its investigational
Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy
Platform (“PRIT”) and bispecific antibodies generated using the
Y-BiClone platform. The Company’s broad and advanced product
pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk),
the first FDA-approved treatment for patients with relapsed or
refractory high-risk neuroblastoma in the bone or bone marrow after
a partial response, minor response, or stable disease to prior
therapy.
Forward-Looking
StatementsStatements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited
to, statements about our business model, including financial
outlook for 2023 and beyond, including estimated operating
expenses, cash burn and DANYELZA product revenue and sufficiency of
cash resources and related assumptions; implied and express
statements regarding the future of the Company’s business,
including with respect to expansion and its goals; the Company’s
plans and strategies, development, commercialization and product
distribution plans, including potential partnerships; expectations
with respect to the Company’s products and product candidates,
including potential territory and label expansion of DANYELZA and
the potential market opportunity related thereto and potential
benefits thereof, and the potential of the SADA Technology and
potential benefits and applications thereof; statements with
respect to DANYELZA as a growing commercial product and SADA as a
differentiated radioimmunotherapy platform positioning the Company
on a path to potentially transform the treatment paradigm for a
variety of cancers and improve patients’ lives; expectations
relating to key anticipated development milestones, including
potential expansion of international commercialization efforts with
respect to DANYELZA development efforts and the SADA Technology,
including potential indications and applications, and the timing
thereof; expectations with respect to current and future clinical
and pre-clinical studies and the Company’s research and development
programs, including with respect to timing and results;
expectations related to the timing of the initiation and completion
of regulatory submissions; additional product candidates and
technologies; expectations regarding collaborations or strategic
partnerships and the potential benefits thereof; expectations
related to the use of cash and cash equivalents, and the need for,
timing and amount of any future financing transaction; expectations
with respect to the Company’s future financial performance; and
other statements that are not historical facts. Words such as
‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’
‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’
‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’
‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’, “guidance,” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Our product candidates and related technologies
are novel approaches to cancer treatment that present significant
challenges. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
factors, including but not limited to: risks associated with the
Company’s financial condition and need for additional capital; the
risks that actual results of the Company’s restructuring plan and
revised business plan will not be as expected; risks associated
with the Company’s development work; cost and success of the
Company’s product development activities and clinical trials; the
risks of delay in the timing of the Company’s regulatory
submissions or failure to receive approval of its drug candidates;
the risks related to commercializing any approved pharmaceutical
product including the rate and degree of market acceptance of
product candidates; development of sales and marketing capabilities
and risks associated with failure to obtain sufficient
reimbursement for products; the risks related to the Company’s
dependence on third parties including for conduct of clinical
testing and product manufacture; the Company’s inability to enter
into partnerships; the risks related to government regulation;
risks related to market approval, risks associated with protection
of the Company’s intellectual property rights; risks related to
employee matters and managing growth; risks related to the
Company’s common stock, risks associated with macroeconomic
conditions, including the conflict between Russia and Ukraine and
sanctions related thereto, the state of war between Israel and
Hamas and the related risk of a larger regional conflict,
inflation, increased interest rates, uncertain global credit and
capital markets and disruptions in banking systems; and other risks
and uncertainties affecting the Company including those described
in the "Risk Factors" section included in the Company’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2022,
the Company’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2023 and future filings and reports by the Company.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and the Company undertakes no
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
DANYELZA®, and Y-mAbs® are registered trademarks
of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney DuganVP, Head of Investor Relationscdu@ymabs.com
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From May 2024 to Jun 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jun 2023 to Jun 2024